Nitrofurantoin Kora Healthcare

Nitrofurantoin, the active ingredient in Nitrofurantoin Kora Healthcare, is a nitrofuran antibiotic presented as an oral formulation for systemic use. It is employed to treat uncomplicated urinary tract infections caused by susceptible bacteria in adult patients and is commonly prescribed in outpatient settings.

GNH USA supplies Nitrofurantoin Kora Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across multiple continents, adhering to local import requirements.

Nitrofurantoin is a nitrofuran antibiotic used to treat infections of the urinary tract. - Uncomplicated urinary tract infection: eradicates susceptible bacteria causing cystitis and urethritis. - Prophylaxis of recurrent urinary tract infection: reduces recurrence in patients with a history of multiple episodes.

Nitrofurantoin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may improve when the medication is taken with food. - Diarrhea: loose, watery stools that can occur during the course of therapy. - Headache: transient headache without accompanying neurological deficits. - Skin rash: mild erythematous rash that usually resolves after discontinuation.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or chronic fibrosis that may develop after prolonged use and requires immediate drug cessation. - Hepatotoxicity: elevation of liver enzymes or hepatitis presenting with jaundice, fatigue and abdominal discomfort. - Hemolytic anemia: rapid destruction of red blood cells, particularly in individuals with glucose‑6‑phosphate dehydrogenase deficiency.

Before prescribing nitrofurantoin, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess creatinine clearance and avoid use in patients with severe renal impairment (eGFR <30 mL/min). - Pregnancy: use only when clearly needed; category B indicates no proven risk in human studies but caution is advised. - G6PD deficiency: screen patients as nitrofurantoin can precipitate hemolysis in deficient individuals. - Concomitant drugs: monitor for interactions that may increase nitrofurantoin levels or toxicity. - Allergic reactions: discontinue if hypersensitivity such as rash, pruritus or anaphylaxis occurs. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Nitrofurantoin may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce nitrofurantoin absorption; separate dosing by at least 2 hours. - Probenecid: decreases renal excretion, increasing plasma concentrations and risk of toxicity. - Fluoroquinolones: concurrent use may increase risk of central nervous system adverse effects. - Cimetidine: may increase nitrofurantoin plasma levels, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: nitrofurantoin can potentiate anticoagulant effect; monitor INR closely. - Oral contraceptives: may reduce efficacy of nitrofurantoin; assess need for alternative contraception. - Diuretics: may affect renal clearance of nitrofurantoin; monitor renal function. - Methenamine: combined use may increase risk of crystalluria; monitor urinary output.